<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05087563</url>
  </required_header>
  <id_info>
    <org_study_id>NLR-210920</org_study_id>
    <nct_id>NCT05087563</nct_id>
  </id_info>
  <brief_title>Neurolens Convergence Insufficiency Study</brief_title>
  <official_title>Randomized Controlled Double Masked Two Arm Cross-over Study of Neurolenses in Subjects With Convergence Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurolens Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurolens Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To understand the benefits of the neurolens Measurement Device and neurolens treatment as it&#xD;
      pertains to treating symptoms related to Convergence Insufficiency. It is a Prospective&#xD;
      randomized double masked two arm performed on a minimum of 100 to a maximum of 150 subjects&#xD;
      identified as symptomatic (CISS questionnaire score equal to or greater than 16) done across&#xD;
      3-10 clinical sites. There are two subgroups: a minimum of 50 in each subgroup(subgroup 1:&#xD;
      pre-presbyopic (18-40 years); subgroup 2: presbyopic subjects(41-60 years).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a two-arm crossover study with two subgroups. Subjects will initially be&#xD;
      assessed for their convergence insufficiency symptoms (convergence insufficiency symptom&#xD;
      score (CISS v-15) questionnaire) and then are provided an updated refractive prescription and&#xD;
      will wear them for 35 ± 5 days. Symptoms will be reassessed after the 35-day control break&#xD;
      in. If the subject's symptoms have subsided, they will be exited from the study and will keep&#xD;
      their lenses. Provided the subject has symptoms (CISS questionnaire score ≥ 16) after their&#xD;
      35-day use of their updated prescription and they continue to meet the inclusion/exclusion&#xD;
      criteria they will proceed to the evaluation portion of the protocol. The first arm receiving&#xD;
      neurolens first and the second arm receiving the control first. The control is a single&#xD;
      vision or PAL lens which yields the BCDVA and BCNVA of a test subject with no prismatic&#xD;
      correction. The neurolens prescribed prism will be based on the practitioner's Rx using the&#xD;
      subject's best response to a prism trial lens and must be within a half prism diopter of the&#xD;
      neurolens value output of the neurolens Measurement Device and providing the subject's BCDVA&#xD;
      and BCNVA. Participants will come back after 35 day wear of their first test lens and the&#xD;
      symptom questionnaire is reassessed. They will be now be crossed over to the second pair of&#xD;
      study lenses (i.e. subjects in the first arm will not receive control lens and the ones in&#xD;
      the second arm will not receive neurolens).Participants will come back after 35 day wear of&#xD;
      their second test lens and the symptom questionnaire is reassessed for the final time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 22, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Prospective randomized double masked two arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Prospective randomized double masked two arm</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Convergence Insufficiency Symptom Score (CISS) questionnaire</measure>
    <time_frame>30-40 days</time_frame>
    <description>Change in Convergence Insufficiency Symptom Score (CISS) with the use of neurolenses compared to control lenses.&#xD;
The minimum response score for each question is 0 and the maximum score is 4. A larger score would indicate a more symptomatic patient&#xD;
Large difference in the cumulative symptom score between the treatment visit and baseline visit would indicate a more effective treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients with Good Stereoacuity</measure>
    <time_frame>30-40 days</time_frame>
    <description>Change in the Convergence Insufficiency Symptom Score (CISS) score with the use of neurolens compared to control lenses in subjects with good stereoacuity.&#xD;
The minimum response score for each question is 0 and the maximum score is 4. A larger score would indicate a more symptomatic patient&#xD;
Large difference in the cumulative symptom score between the treatment visit and baseline visit would indicate a more effective treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Binocular Vision Disorder</condition>
  <condition>Convergence Insufficiency</condition>
  <condition>Computer Vision Syndrome</condition>
  <arm_group>
    <arm_group_label>Neurolens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Our proprietary contoured prism lens design, commercially known as neurolens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control lens</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A simple refractive error correction lens</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neurolens spectacle lens</intervention_name>
    <description>spectacle lens</description>
    <arm_group_label>Neurolens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo spectacle lens</intervention_name>
    <description>spectacle lens for refractive correction</description>
    <arm_group_label>Control lens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, and between 18-60 years of age at the time of signing the informed&#xD;
             consent.&#xD;
&#xD;
          -  Best Corrected distance and near acuity are equal to or better than 20/25 Snellen&#xD;
             Equivalent in each eye.&#xD;
&#xD;
          -  Best Corrected distance and near binocular acuity are equal to or better than 20/25&#xD;
             Snellen Equivalent.&#xD;
&#xD;
          -  Symptomatic as indicated by the CISS questionnaire (Score equal to or greater than 16)&#xD;
&#xD;
          -  Updated distance spectacle prescription must match the following&#xD;
&#xD;
               1. Spherical power inclusive between +4.00D to -8.00D&#xD;
&#xD;
               2. Cylinder power no more than -4.00Dcyl&#xD;
&#xD;
               3. ADD power i. Subgroup 1: No ADD ii. Subgroup2: minimum +1.00D ADD&#xD;
&#xD;
          -  Subjects' eye alignment tests must match the following:&#xD;
&#xD;
             a. Successful measurement on the neurolens Measurement Device (Acceptable MQI and a&#xD;
             numerical neurolens Value, no Low MQI or Convergence Excess)&#xD;
&#xD;
          -  Near point of convergence greater than or equal to 5cms&#xD;
&#xD;
          -  Capable of committing to the duration of the study.&#xD;
&#xD;
          -  Willing to comply with study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who need a vertical prism.&#xD;
&#xD;
          -  Previously has worn neurolenses.&#xD;
&#xD;
          -  Subjects who need a near add less than 1.00D&#xD;
&#xD;
          -  Use of contact lenses during the study&#xD;
&#xD;
          -  Lack of binocular vision, including strabismus, amblyopia, or suppression.&#xD;
&#xD;
          -  Greater than 20 prism diopter of eye misalignment.&#xD;
&#xD;
          -  Aniseikonia greater than 3.00D spherical equivalent difference between eyes&#xD;
&#xD;
          -  Prior ocular surgery that in the estimation of the practitioner induces corneal&#xD;
             scarring (RK, Corneal Transplant, etc.) or prior surgery involving the extraocular&#xD;
             muscles (strabismus surgery). Surgeries that do not affect these parameters such as&#xD;
             LASIK, PRK, or pterygium surgery are allowed.&#xD;
&#xD;
          -  Anterior segment conditions that could obfuscate or obscure reflections from the&#xD;
             cornea, or reduce visual acuity, including but not limited to corneal scarring, large&#xD;
             pinguecula, pterygium, keratoconus, dermatochalasis, ptosis, exophthalmos or cataract.&#xD;
&#xD;
          -  Clinical dry eye (defined as tear break-up time of less than 5 seconds)&#xD;
&#xD;
          -  Intraocular pressures greater than 25 mmHg in either eye or uncontrolled glaucoma&#xD;
&#xD;
          -  Macular disease, or any posterior segment finding which in the opinion of the&#xD;
             investigator is visually and/or clinically significant&#xD;
&#xD;
          -  Change in acute or prophylactic migraine treatment medication or dosage within the&#xD;
             previous two months.&#xD;
&#xD;
          -  Diabetes with ocular manifestation&#xD;
&#xD;
          -  Previous head or neck trauma (for instance, car accident, etc.) requiring medical&#xD;
             intervention.&#xD;
&#xD;
          -  Open lesions or sores around the chin or eyes that will make contact with the device&#xD;
             and may be subject to contraction or spread of infection.&#xD;
&#xD;
          -  Physical tremors or muscle spasms that prevent a subject from sitting still.&#xD;
&#xD;
          -  A history of seizures or seizure disorder.&#xD;
&#xD;
          -  Women who are pregnant or lactating at the time of the study entry&#xD;
&#xD;
          -  Mental incapacity that prevents a subject from being able to follow simple&#xD;
             instructions such as &quot;look at the target.&quot;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corina Van de Pol, OD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Neurolens Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vivek Labhishetty, PhD</last_name>
    <phone>(949) 516-7060</phone>
    <phone_ext>1100</phone_ext>
    <email>vivek.labhishetty@neurolenses.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jesus Cortes, BA</last_name>
    <phone>(949) 516-7060</phone>
    <phone_ext>1100</phone_ext>
    <email>jesus.cortes@neurolenses.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Carmel Mountain Vision Care</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92129</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Heather Szczygiel</last_name>
      <email>Heather@cmvcmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fort Collins Family Eye Care</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80526</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lisa Skinner</last_name>
      <email>lisa@fcfamilyeyecare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Total Vision Eyecare</name>
      <address>
        <city>Manchester</city>
        <state>Connecticut</state>
        <zip>06040</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Elizabeth Anamani</last_name>
      <email>lanamani@totalvisioneyecare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suarez Optical</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Melissa Davis</last_name>
      <email>melissa.suarez001@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rock River Eye Care</name>
      <address>
        <city>Rock Rapids</city>
        <state>Iowa</state>
        <zip>51246</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lisa Jurgens</last_name>
      <email>lisa.jurgens@rockrivereyecare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gaddie Eye Centers</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Vicki Miles</last_name>
      <email>vmiles@gaddieeye.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Waterfront Eye Care</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Rishad Ioussifov</last_name>
      <email>rishad@swec.us</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eyes and Ears</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kaileigh Reichert</last_name>
      <email>kaileigh@myeyesandears.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 8, 2021</study_first_submitted>
  <study_first_submitted_qc>October 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>convergence insufficiency</keyword>
  <keyword>neurolenses</keyword>
  <keyword>computer vision syndrome</keyword>
  <keyword>binocular vision</keyword>
  <keyword>non-strabismic disorder</keyword>
  <keyword>digital vision syndrome</keyword>
  <keyword>headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vision Disorders</mesh_term>
    <mesh_term>Ocular Motility Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will be providing a backend read-only excel spreadsheet of the raw data that was entered on the digital data platform provided to the clinical site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available along with the publication for at least 5 years.</ipd_time_frame>
    <ipd_access_criteria>On request.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

